June 2024. Volume 20. Number 2

In children with uncontrolled severe pediatric allergic asthma, the use of omalizumab could be a cost-effective option

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Nieto Cid M, Garriga Baraut T, Plaza Martín A, Tortajada Girbés M, Torres Borrego J, Lozano Blasco J, et al. Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma. Results of a real-life study in Spain. Pediatr Allertgy Immunol. 2023;34:e13942.

Reviewers: Ortega Páez E1, González Rodríguez MP2.
1Pediatra. CS Góngora. Distrito Granada-Metropolitano. Granada. España.
2Pediatra. CS Barrio del Pilar. Madrid. España.
Correspondence: Eduardo Ortega Páez. Email: edortegap@gmail.com
Reception date: 15/01/2024
Acceptance date: 06/02/2024
Publication date: 10/04/2024

Abstract

Authors´ conclusions: the use of omalizumab is a cost-effective option for most children with uncontrolled severe pediatric allergic asthma, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.

Reviewers´ commentary: according to the results of this study, the use of omalizumab in the treatment of severe asthma, despite its cost, appears to be efficient, being more cost-effective in the prevention of exacerbations than in the continuous control of the disease. These results are specifically applicable to our hospital setting.

How to cite this article

Ortega Páez E, González Rodríguez P. En niños con asma grave alérgica el tratamiento con omalizumab podría ser costoefectivo. Evid Pediatr. 2024;20:17.

AVC | Critically appraised articles

Nieto Cid M, Garriga Baraut T, Plaza Martín A, Tortajada Girbés M, Torres Borrego J, Lozano Blasco J, et al. Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma. Results of a real-life study in Spain. Pediatr Allertgy Immunol. 2023;34:e13942.

Reviewers: Ortega Páez E1, González Rodríguez MP2.
1Pediatra. CS Góngora. Distrito Granada-Metropolitano. Granada. España.
2Pediatra. CS Barrio del Pilar. Madrid. España.
Correspondence: Eduardo Ortega Páez. Email: edortegap@gmail.com
Reception date: 15/01/2024
Acceptance date: 06/02/2024
Publication date: 10/04/2024

How to cite this article

Ortega Páez E, González Rodríguez P. En niños con asma grave alérgica el tratamiento con omalizumab podría ser costoefectivo. Evid Pediatr. 2024;20:17.

10/04/2024

Linked Comment